US Bancorp DE Grows Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

US Bancorp DE grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 12.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 83,383 shares of the medical instruments supplier’s stock after purchasing an additional 9,190 shares during the quarter. US Bancorp DE’s holdings in Becton, Dickinson and Company were worth $20,104,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Livelsberger Financial Advisory purchased a new position in Becton, Dickinson and Company during the third quarter worth about $26,000. Sound Income Strategies LLC lifted its holdings in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares during the period. Opal Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company in the second quarter worth approximately $45,000. Abound Wealth Management increased its position in Becton, Dickinson and Company by 96.0% during the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 96 shares during the last quarter. Finally, Chilton Capital Management LLC raised its stake in Becton, Dickinson and Company by 1,233.3% during the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 185 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

BDX has been the subject of several research reports. Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Evercore ISI increased their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Raymond James cut their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $235.24 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The firm’s fifty day moving average price is $237.56 and its 200 day moving average price is $235.05. The company has a market capitalization of $67.99 billion, a price-to-earnings ratio of 48.40, a price-to-earnings-growth ratio of 1.77 and a beta of 0.42. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $259.92.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. During the same period in the previous year, the company earned $2.96 earnings per share. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, research analysts forecast that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.